Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM
Blood Adv
.
2020 Oct 13;4(19):4834-4837.
doi: 10.1182/bloodadvances.2020002590.
Authors
Neeraj Saini
1
,
Qaiser Bashir
1
,
Denái R Milton
2
,
Guilin Tang
3
,
Ruby Delgado
1
,
Gabriela Rondon
1
,
Uday R Popat
1
,
Chitra M Hosing
1
,
Yago Nieto
1
,
Partow Kebriaei
1
,
Amin M Alousi
1
,
Rohtesh Mehta
1
,
Samer Srour
1
,
Issa F Khouri
1
,
Donna M Weber
4
,
Sheeba K Thomas
4
,
Hans C Lee
4
,
Krina K Patel
4
,
Robert Z Orlowski
4
,
Richard E Champlin
1
,
Muzaffar H Qazilbash
1
Affiliations
1
Department of Stem Cell Transplantation and Cellular Therapy.
2
Department of Biostatistics.
3
Department of Hematopathology, and.
4
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
PMID:
33027527
PMCID:
PMC7556152
DOI:
10.1182/bloodadvances.2020002590
No abstract available
MeSH terms
Busulfan*
Hematopoietic Stem Cell Transplantation*
Melphalan
Transplantation Conditioning
Transplantation, Autologous
Substances
Busulfan
Melphalan
Grants and funding
P30 CA016672/CA/NCI NIH HHS/United States